90721-34-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Isoquinolinamine,8-bromo-(9CI) is used as a building block for the synthesis of other compounds in the pharmaceutical industry. Its unique structure, including the bromine atom, may contribute to the development of new drugs with specific therapeutic properties.

Upstream product

• 252861-41-9 8-bromo-5-nitroisoquinoline 
• 1125-60-6 isoquinolin-5-ylamine 

Downstream Products

• 581810-37-9 N-(8-bromoisoquinolin-5-yl)-N'-(2,4-dichlorobenzyl)urea 
• 581810-99-3 N-(8-bromoisoquinolin-5-yl)-N'-(2,4-dichlorobenzyl)urea hydrochloride 

Relevant academic research and scientific papers

MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER

The present disclosure provides compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, L1, R2 B, Q and E are as defined as set forth in

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.